Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Gross Margin (2021 - 2024)

Goldenwell Biotech filings provide 4 years of Gross Margin readings, the most recent being 53.8% for Q4 2024.

  • On a quarterly basis, Gross Margin rose 2572.0% to 53.8% in Q4 2024 year-over-year; TTM through Sep 2025 was 39503.16%, a 3953900.0% decrease, with the full-year FY2024 number at 46.04%, up 977.0% from a year prior.
  • Gross Margin hit 53.8% in Q4 2024 for Goldenwell Biotech, up from 50.36% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 53.8% in Q4 2024 to a low of 28.08% in Q4 2023.
  • Median Gross Margin over the past 4 years was 52.53% (2021), compared with a mean of 49.7%.
  • Biggest five-year swings in Gross Margin: plummeted -402bps in 2023 and later surged 2572bps in 2024.
  • Goldenwell Biotech's Gross Margin stood at 52.54% in 2021, then rose by 0bps to 52.71% in 2022, then tumbled by -47bps to 28.08% in 2023, then skyrocketed by 92bps to 53.8% in 2024.
  • The last three reported values for Gross Margin were 53.8% (Q4 2024), 50.36% (Q2 2024), and 28.08% (Q4 2023) per Business Quant data.